Exelixis, Inc. EXEL is scheduled to report fourth-quarter 2018 results on Feb 12, after the market closes.
Exelixis’ shares have gained 7.6% in the past six months compared with the industry’s decline of 13.5%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,